Kiniksa Pharmaceuticals International, plc (KNSA)
| Market Cap | 4.88B +135.7% |
| Revenue (ttm) | 754.05M +56.7% |
| Net Income | 73.06M |
| EPS | 0.91 |
| Shares Out | 76.94M |
| PE Ratio | 69.89 |
| Forward PE | 51.68 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 443,078 |
| Open | 65.16 |
| Previous Close | 65.38 |
| Day's Range | 62.60 - 65.71 |
| 52-Week Range | 26.27 - 67.53 |
| Beta | 0.07 |
| Analysts | Strong Buy |
| Price Target | 65.13 (+2.66%) |
| Earnings Date | Jul 28, 2026 |
About KNSA
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericard... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for KNSA stock is "Strong Buy." The 12-month stock price target is $65.13, which is an increase of 2.66% from the latest price.
News
Kiniksa price target raised to $72 from $59 at Wedbush
Wedbush raised the firm’s price target on Kiniksa (KNSA) to $72 from $59 and keeps an Outperform rating on the shares. Arcalyst heads into Q2 earnings with continued commercial momentum…
Kiniksa Pharmaceuticals International, Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Strong commercial growth and expanded guidance for ARCALYST are supported by increasing prescriber adoption and a shift to chronic disease management. Pipeline assets KPL-387 and KPL-1161 are advancing, with key clinical milestones expected in 2024, and the company remains financially robust and focused on innovation.
Kiniksa Pharmaceuticals International, Transcript: Jefferies Global Healthcare Conference 2026
Strong Q1 growth led to raised 2026 revenue guidance for ARCALYST, with expanding physician adoption and ongoing efforts to increase patient awareness. Pipeline progress includes KPL-387 phase II data expected in H2 and KPL-1161 entering phase I by year-end. Cash reserves remain robust at $468 million.
Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences
LONDON, May 29, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in fireside chats at the following investor conferen...
Kiniksa price target raised to $64 from $62 at Canaccord
Canaccord raised the firm’s price target on Kiniksa (KNSA) to $64 from $62 and keeps a Buy rating on the shares. The firm noted Kiniksa reported 1Q26 earnings. Top-line revenue…
Kiniksa price target raised to $59 from $58 at Wedbush
Wedbush raised the firm’s price target on Kiniksa (KNSA) to $59 from $58 and keeps an Outperform rating on the shares. The firm notes Q1 Arcalyst revenue of $214.3M beat…
Kiniksa price target raised to $60 from $50 at Citi
Citi raised the firm’s price target on Kiniksa (KNSA) to $60 from $50 and keeps a Buy rating on the shares.
Kiniksa price target raised to $71 from $58 at Jefferies
Jefferies analyst Roger Song raised the firm’s price target on Kiniksa (KNSA) to $71 from $58 and keeps a Buy rating on the shares after a “beat-and-raise” Q1 report. Management…
Kiniksa Pharmaceuticals International, Earnings Call Transcript: Q1 2026
Q1 2026 saw ARCALYST revenue rise 56% year-over-year to $214.3M, driving net income to $22.6M and prompting a raised full-year revenue outlook. Strong commercial execution, new prescriber growth, and targeted DTC campaigns support continued momentum.
Kiniksa Pharmaceuticals International, Earnings release: Q1 2026
Kiniksa Pharmaceuticals International, released its Q1 2026 earnings on April 28, 2026, summarizing the period's financial results.
Kiniksa Pharmaceuticals International, Slides: Q1 2026
Kiniksa Pharmaceuticals International, has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 28, 2026.
Kiniksa Pharmaceuticals International, Quarterly report: Q1 2026
Kiniksa Pharmaceuticals International, has published its Q1 2026 quarterly earnings report on April 28, 2026.
Kiniksa reports Q1 EPS 27c, consensus 16c
Reports Q1 revenue $214.27M, consensus $206.09M. “Five years from launch, Kiniksa (KNSA) continues to deliver strong ARCALYST revenue growth, driven by expanding adoption of IL-1alpha and IL-1beta inh...
Kiniksa raises FY26 revenue view to $930M-$945M from $900M-$920M
Consensus $913.27M. The company said, “Kiniksa (KNSA) expects 2026 ARCALYST net product revenue of between $930 million and $945 million, compared to prior guidance of between $900 million and $920…
Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution
– ARCALYST ® (rilonacept) Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth – – ARCALYST 2026 expected net product revenue increased to $930 - $945 million – – KPL-...
Kiniksa Pharmaceuticals to Report First Quarter 2026 Financial Results on April 28, 2026
LONDON, April 23, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 28, 2026 at ...
Kiniksa price target raised to $58 from $53 at Wedbush
Wedbush raised the firm’s price target on Kiniksa (KNSA) to $58 from $53 and keeps an Outperform rating on the shares. The firm notes Arcalyst heads into Q1 earnings with…
Kiniksa Pharmaceuticals International, Proxy statement: Proxy filing
Kiniksa Pharmaceuticals International, filed a proxy statement on April 16, 2026, providing details for shareholder voting and corporate governance matters.
Kiniksa Pharmaceuticals International, Proxy statement: Proxy filing
Kiniksa Pharmaceuticals International, filed a proxy statement on April 16, 2026, providing details for shareholder voting and corporate governance matters.
Kiniksa launches direct-to-consumer campaign for Arcalyst
Kiniksa (KNSA) announced the launch of Heart’s Home, a direct-to-consumer campaign for Arcalyst, the FDA approved therapy for recurrent pericarditis. This multi-faceted campaign is aimed at identifyin...
Kiniksa Pharmaceuticals Launches Targeted Direct-To-Consumer TV Campaign for ARCALYST® (rilonacept) in Recurrent Pericarditis
– Educational campaign to raise awareness of recurrent pericarditis and to empower patients to discuss ARCALYST with their healthcare provider – – Media accompanying this announcement is available by ...
Kiniksa Pharmaceuticals International, Transcript: TD Cowen 46th Annual Health Care Conference
Revenue grew 62% in 2025, driven by increased patient adds, prescriber expansion, and longer therapy duration, with only 18% market penetration so far. Pipeline progress includes upcoming Phase II data for KPL-387 and a Phase I start for KPL-1161, while disciplined capital allocation supports ongoing growth.
Kiniksa Pharmaceuticals to Present at TD Cowen 46th Annual Health Care Conference
LONDON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the TD Cowen 46th Annual Heal...